Monday, September 25, 2023
China Approves the World's First Vaccine against XBB Descendent Lineages of SARS-CoV-2 for Emergency Use
  SocialTwist Tell-a-Friend  

CHENGDU, China, June 9, 2023 /PRNewswire/ -- On June 8th, 2023, Coviccine ® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 cell) developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities in China. This is the first COVID-19 vaccine in the world approved for EUA against XBB descendent lineages of SARS-CoV-2. It demonstrates that China is leading the world in the development of COVID-19 vaccines.  

WestVac Biopharma and its subsidiary company WestVac Biopharma (Guangzhou) leveraged the rapid response of the insect cell expression platform on constructing the vector for Coviccine ® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 Cell), which is of high purity and high quality for human use. The subunit vaccine antigen is precisely designed based on the structure of the targeting S-RBD and HR proteins of the COVID-19 subvariants XBB.1.5 and BA.5 and self-assembled into stable trimeric protein particles with squalene-based oil-in-water emulsion adjuvant added after purification and mixing. This novel adjuvant significantly raises the titer of neutralizing antibodies, which enables the trimeric protein vaccine to induce a higher level T-cell immune response. Studies have shown that Coviccine ® Trivalent XBB.1.5 induced a high titer of neutralizing antibodies against multiple subvariants, including Omicron subvariants XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, BA.2.75. 14 days after injection of this product, the protective efficacy against XBB.1, XBB.1.5, XBB1.9 is 93.28% with an excellent safety profile, demonstrating that it is a broad-spectrum COVID-19 vaccine against multiple prevalent subvariants locally and internationally.

The XBB.1.5 variant had gradually become the major circulating variant in various parts of the world by the beginning of 2023. With the professional guidance and support from the State Council's Joint Prevention and Control Mechanism's vaccine R&D team, the scientific team of WestVac Biopharma/West China Medical Center, Sichuan University overcame all hurdles and successfully developed a vaccine covering XBB family of variants.

Early May, China CDC expert noticed that the transmission and immune escape capability of XBB variants is much stronger than that of the early circulating Omicron variants. The XBB.1 descendent lineages currently predominate SARS-CoV-2 circulation globally. As of the end of May, XBB family of variants accounted for 98.1% of all variants in the United States. In China, newly detected XBB variants have increased gradually and now exceed 90%.

The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) advised on May 18 that new formulations of COVID-19 vaccines should aim to induce antibody responses that neutralize XBB descendent lineages. The rate of "second infection" is rising. Experts urge prompt prevention, immunization against COVID-19, particularly for people with high-risk infection, the elderly, people with underlying diseases and those who are immunocompromised to get a vaccine covering SARS-CoV-2 variants.

WestVac Biopharma uses the international advanced insect cell recombinant protein vaccine platform to develop Coviccine ® Trivalent XBB.1.5 which has been approved for EUA in China. WestVac's COVID-19 vaccine offers a unique option for COVID-19 prevention, is crucial for the prevention of the current XBB descendent lineages and contributes significantly to the ongoing management of the COVID-19 epidemic.


About WestVac Biopharma

WestVac Biopharma Co., Ltd. is an innovative biopharmaceutical company, capable of doing the full spectrum of research, manufacturing, and commercialization of products. WestVac Biopharma has been selected successfully on the list of unicorn companies from 2021 to 2023. WestVac Biopharma Co., Ltd. is located in Chengdu of West China while WestVac Biopharma (Guangzhou), a wholly-owned subsidiary company of WestVac Biopharma., is located in Guangzhou Economic Development Zone.

WestVac Biopharma Co., Ltd. has completed construction of 5,000-litre and 3,000-litre insect cell recombinant protein vaccine production lines with an annual production capacity of 100 million doses. The GMP production lines were well established with the "Drug Production License" in place. WestVac Biopharma (Guangzhou) has completed scale-up construction of insect cell recombinant protein vaccine production lines with an annual production capacity of 100 million doses.

In December 2022, Coviccine ®-Recombinant COVID-19 Vaccine (Sf9 cell) developed by WestVac Biopharma was approved by relevant authorities for EUA in China.

Photo -  
Photo -

Cision View original content:

More News by PR Newswire India

Over 20,000 avail benefit at free mega health camp organised by Chandigarh Welfare Trust to celebrate 73rd birthday of PM Modi

Huawei Accelerates Intelligent Healthcare with the Innovative Digital Medical Technology Solution

Huawei High-Quality 10 Gbps CloudCampus Accelerates Intelligent Transformation Across Industries

Hexaware Appoints Anton Tomchenko as Chief Revenue & Solutions Officer for Digital & Software Services

Xinhua Silk Road: Dev't index witnesses progress of int'l shipping center construction in Shanghai

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology

Religare Broking Takes A Global Leap to Serve NRIs: Hosted IGI Conference in Dubai France obtains the maintenance of VAT at the reduced rate of 5.5% on the Art Market, a major victory with very considerable advantages according to Artprice.

Safer, Inclusive Schools Critical for Children's Learning: Coalition for Good Schools

LRQA verifies Bridgestone's plant in India as carbon neutral against international standard PAS 2060

A23 launches new brand campaign featuring Shah Rukh Khan; Unveils new A23 Poker app

VVDN Technologies and Axiado Collaborate on Open Compute Platform Compliant data center and Telco O-RAN servers

Huawei Upgrades the CloudWAN 3.0 Solution, Accelerating the Intelligent Era

Redefine Security with the All-New Huawei HiSec Intelligent Security Portfolio and the Powerful HiSec SASE Security Solution

Huawei Launches Three Product Portfolios for the Commercial Market to Build High-Quality Connections


Come Discover Colorful Guiyang featuring "Thousand Parks, Thousand Paths"

Casio to Release League of Legends G-SHOCK Watches

Campus With A Conscience hosts a week-long UN festival

France Announces €40 Million in New Funding to Education Cannot Wait at Global Citizen Festival

CGTN: 'Heart to Heart': How can Hangzhou Asiad boost unity, friendship across Asia?

Education Icon Awards 2023 organized by Kiteskraft Productions LLP

Office of the Executive Committee of the WMC: Anhui Strengthens Scientific and Technological Innovation Capacity to Attract Multinational Enterprises


TECNO Globally Launches PHANTOM V Flip 5G: Representing Flip in Style and Perfect in Pocket

West Bengal's 4th Vande Bharat Express t...
'Day not far when there will be mob lync...
Flagged off by PM Modi, Vande Bharat Exp...
Over 500 foreign buyers register on thir...
Odisha CM Naveen Patnaik lauds PM Modi o...
Hyderabad showcases ISRO's Chandrayaan-3...
 Top Stories
China pushes its hegemonic proposal... 
India heading to ICC Cricket World ... 
Revolutionizing the Indian Jewelry ... 
Sidharth Malhotra to Varun Dhawan, ... 
CM Khattar flags off cyclothon for ... 
SC asks Chandrababu Naidu’s lawyer ... 
Make Upskilling Decision Faster and... 
5 killed after car collides with tr...